Angiocrine Bioscience focuses on developing innovative cellular therapies aimed at harnessing the reparative capabilities of E-CEL Therapies. These therapies are designed to positively impact patients' lives by promoting tissue repair and regeneration. The company emphasizes the potential of its technologies to address various medical conditions through advanced cellular treatments, which leverage the body's natural healing processes.

The leadership team at Angiocrine Bioscience brings extensive experience in biotechnology and healthcare, with a strong emphasis on strategic development in cellular immunotherapy and regenerative therapies. Their expertise spans various aspects of life sciences, including operational management, clinical development, and regulatory affairs, which positions the company to effectively advance its therapeutic pipeline. The integration of scientific research and clinical application is central to Angiocrine's mission, aiming to translate innovative cellular technologies into meaningful patient outcomes.

United States

Angiocrine Bioscience is a private, clinical stage engineered cell therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions.

Our team is developing a pipeline of proprietary engineered endothelial cell (E-CEL® ) therapies for treating multiple life-threatening hemato-oncologic and  immunologic conditions, as well as, regenerating tissues and organs that have been injured or damaged by diseases.

Angiocrine Bioscience

Company Details